Neurogen Corporation Elects Craig Saxton, M.D. to Board of Directors
BRANFORD, Conn., Jan. 31 /PRNewswire-FirstCall/ -- Neurogen Corporation (Nasdaq: NRGN - news), a leading small molecule drug discovery and development company, announced today that it has elected Craig Saxton, M. D. to its Board of Directors.
Dr. Saxton retired recently from a distinguished career with Pfizer Inc (NYSE: PFE - news), where he served as Executive Vice President, Pfizer Global Research and Development and Vice President of Pfizer, Inc. Dr. Saxton was responsible for the development of all drugs discovered or licensed by Pfizer for human therapeutic use and played a pivotal role in the growth of Pfizer's extensive drug pipeline.
William H. Koster, PhD, President and CEO of Neurogen, commented, ``We very much look forward to Craig's contribution in moving Neurogen's vision forward. His experience at ensuring the successful progression of new pharmaceuticals through the research and development cycle complements the core strengths of our Board.''
Dr. Saxton joined Pfizer in 1976 in its European R&D headquarters in the United Kingdom and moved to the U.S. in 1981 as Senior Associate Medical Director of International Pharmaceuticals, becoming Vice President and Medical Director of Pfizer International, Inc. in 1982. He returned to Pfizer's Global Research and Development Division in Groton in 1988 as Senior Vice President, World Wide Clinical Research, and was promoted to Executive Vice President of the division in 1993.
Dr. Saxton holds a B.S. degree in anatomy from Leeds University in the United Kingdom, where he also earned his doctorate in medicine. He serves on the Boards of Directors of Tularik Corporation, Veritas Medicine, and the African Medical and Research Foundation. He is a member of the American Academy of Pharmaceutical Physicians and the Connecticut Academy of Science and Engineering. He has conducted significant research into the metabolic consequences of cardiac disease, authoring numerous papers on the subject in respected scientific journals.
Neurogen Corporation (Nasdaq: NRGN - news) is a leading small molecule drug discovery and development company targeting new drug candidates to improve the lives of patients suffering from neurological, metabolic, and inflammatory disorders. Neurogen has generated a portfolio of compelling new drug programs through its fully integrated drug discovery platform, successfully solving complex issues in the discovery of small molecule drugs for valuable targets. Neurogen's strategy is to advance a mix of proprietary drugs independently and, when advantageous, utilize strategic collaborations with world-class pharmaceutical companies during the drug development process to obtain additional resources and to access complementary expertise. Neurogen's Accelerated Intelligent Drug Discovery (AIDD) process is a key discriminator in the Company's ability to rapidly and cost effectively screen for active compounds during the drug discovery process. |
